Medicare is pulling the easy money for 'breakthrough' medical devices

For six years, the FDA's "breakthrough" designation functioned as a quiet Medicare subsidy. As of fiscal year 2028, that link is broken.

Medicare will stop paying hospitals a premium for adopting medical devices that carry the FDA's "breakthrough" label but have not yet shown they beat existing treatments, according to a final rule published by the Centers for Medicare & Medicaid Services this week and reported by STAT+ on Monday. The rollback applies to both inpatient and outpatient settings and takes effect at the start of fiscal year 2028.

"Breakthrough" is a regulatory label the FDA grants to devices it expects to work better than what is already on the market, not a clinical verdict. The two things are not the same. Under a 2020 rule issued by the first Trump administration, the label came with an automatic payment shortcut: breakthrough devices were deemed both new and automatically meeting Medicare's "substantial clinical improvement" standard, a key bar for receiving NTAP add-on payments.

CMS is now repealing that shortcut. Going forward, breakthrough devices will have to clear the same three criteria as any other technology seeking the add-on: newness, an inadequate existing payment, and demonstrated improvement over the current standard of care. The change applies in parallel to device pass-through payments in the outpatient system, according to a Gardner Law analysis of the proposed rule.

The agency said the change "ensures that additional Medicare payments are used to support Medicare beneficiaries' access to innovations that are demonstrated to improve outcomes compared to the currently available treatment," and pointed to "concerns with the limited evaluation process" for add-on applications.

Roughly 69 percent of traditional NTAP applications have been denied solely on the substantial clinical improvement bar, with another 13 percent denied for SCI combined with other reasons, according to an analysis cited in a Blythe Karow Substack post with former CMS Chief Medical Officer Dr. Lee Fleisher. CMS has long signaled that a label-based shortcut made that bar easier to clear for one category of device than for any other.

The change lands on three audiences. Patients may see slower access to expensive new tools while evidence accumulates. Hospitals lose a financial cushion that helped them justify the capital cost of adopting cutting-edge devices, since NTAP can add up to three years of supplemental payments when the standard inpatient payment is inadequate. And device makers face a higher bar before Medicare subsidizes adoption, which is why the trade group AdvaMed called the original proposal "disappointing" and warned it would "roll back" progress.

The rule does not eliminate NTAP itself, only the breakthrough-specific shortcut. CMS also moved in parallel on the coverage side. Nine days after the April 14, 2026 NTAP proposal, the agency and FDA jointly announced a new RAPID coverage pathway, and CMS paused the older Transitional Coverage for Emerging Technologies (TCET) program, suggesting a shift away from breakthrough-linked fast tracks and toward an evidence-and-alignment model for new device coverage.

For hospitals and device makers, the FY 2028 effective date is short enough that capital planning and evidence budgets are already in motion. For patients, the next milestone is whether the higher bar produces the slower, more rigorous evidence base the rule's authors promise, or simply slower access to devices that might have helped.